CLNNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Clene Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.29+0.19 (+6.13%)
Close on Oct 19, 2026
- Market cap
- $40.74M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$5.21 (−61.29%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Clene Inc. saw revenue fall 31.1% to $197.00K over the twelve months to Jun 30, 2026. Free cash flow was -$18.59M.
Revenue
$197.00K
-31.1% vs. a year earlier
Operating income
-$20.55M
TTM Q2 2026
Free cash flow
-$18.59M
FY2025
EPS, diluted
-$3.48
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $40.74M
- P/E ratio
- –
- Price to sales
- 206.80
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -45.62%
Fundamentals
- Revenue
- $197.00K
- Net income
- -$39.52M
- EPS, diluted
- -$3.48
- Free cash flow
- -$18.59M
- Book value per share
- -$2.00
- Diluted shares
- 12M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$197.00K-31.1% YoY
Gross profit
$138.00K-40.0% YoY
Operating income
-$20.55M
Net income
-$39.52M
EPS, diluted
-$3.48
Free cash flow
–
Reported periodTrailing twelve months